Effect on Cognitive Function of a Treatment With Aripiprazole

Phase 4CompletedNCT00329810

Otsuka Pharmaceutical Development & Commercialization, Inc.500 enrolled

Overview

To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

500

Conditions

Schizophrenia

Interventions

AripiprazoleDRUG

Tablets, oral, 15 mg, once daily, 12 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Schizophrenia * score of 2-6 in the CGI-S scale at basline * ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment Exclusion Criteria: * women of child bearing potential * women pregnant or breast feeding * patients with a score of 0,-1 or 7 * substance use

Outcomes

Primary Outcomes

Clinical Global Impression scale at endpoint

Secondary Outcomes

Change in Clinical Global Impression scale and cognition scales at endpoint

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.